Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma

Abstract

Subgroup-specific analysis reconciles prior conflicting publications and confirms that TP53 mutations are enriched among SHH medulloblastomas, in which they portend poor outcome and account for a large proportion of treatment failures in these patients.